TrialFrontiers in public health2025

International cost-effectiveness analysis in osimertinib after chemoradiotherapy in stage III EGFR-mutated non-small cell lung cancer.

Diya Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.